As Of                Filer                Filing    For·On·As Docs:Size              Issuer               Agent

 1/07/03  Intermune Inc                     8-K:5,7     1/07/03    2:57K                                    Merrill Corp/New/FA

Document/Exhibit                   Description                      Pages   Size 

 1: 8-K         Current Report                                      HTML     22K 
 2: EX-99.1     Miscellaneous Exhibit                               HTML     22K 

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

Current Report Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): January 7, 2003

 

 

INTERMUNE, INC.

(Exact name of registrant as specified in its charter)

 

 

3280 Bayshore Boulevard

Brisbane, CA 94005

(Address and registrant’s principal executive offices and zip code)

 

 

Registrant’s telephone number, including area code: (415) 466-2200

 

Item 5.                    Other Events

 

On January 6, 2003, InterMune, Inc. issued a press release entitled “ Intermune to Update Investors at the 21st Annual JP Morgan H&Q Healthcare Conference,” announcing that it expects 2002 revenue will be at the upper end of its previously estimated range of $105-110 million, and announcing preliminary survival data from an exploratory three to five month follow-up observational period of its double-blind, placebo-controlled Phase III clinical trial of Actimmune for the treatment of idiopathic pulmonary fibrosis.  A copy of such press release is attached hereto as Exhibit 99.1 and is incorporated by reference herein.

 

In February 2003, Intermune will update revenue guidance concerning its products.

 

Item 7.                    Financial Statements, Pro Forma Financial Information and Exhibits

 

(c)           Exhibits.

 

Number		Description
99.1		Press Release entitled “Intermune to Update Investors at the 21st Annual JP Morgan H&Q Healthcare Conference,” dated January 6, 2003.

 

 

 

 

 

 

 

 

 

 

2

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

 

		INTERMUNE, INC.
Dated: January 7, 2003		By:	/s/  STEPHEN N. ROSENFIELD
			Stephen N. Rosenfield
			Senior Vice President of Legal Affairs

 

 

 

 

 

 

 

 

 

 

 

 

 

3

 

EXHIBIT INDEX

 

Number		Description
99.1		Press Release entitled “Intermune to Update Investors at the 21st Annual JP Morgan H&Q Healthcare Conference,” dated January 6, 2003.

 

 

 

 

 

 

 

 

 

 

 

 

4